Federal Register / Vol. 70, No. 196 / Wednesday, October 12, 2005 / Notices 59349 

Rita. This deviation will allow Federal 

agencies to purchase premium gasoline 

for government owned and leased 

vehicles when lower grade gasoline is 

not available. This deviation can be 

found at www.gsa.gov/vehiclepolicy 

and clicking on ‘‘Deviation from 41 CFR 

102–34.335’’. 

DATES: The deviation announced in this 

notice is effective September 8, 2005. 

FOR FURTHER INFORMATION CONTACT: For 

clarification of content, contact General 

Services Administration, Office of 

Governmentwide Policy, Office of 

Travel, Transportation and Asset 

Management, at (202) 501–1777 and cite 

the deviation regarding motor vehicle 

management dated September 30, 2005. 

SUPPLEMENTARY INFORMATION: 

A. Background 

Federal Management Regulation 

(FMR) section 102–34.335 (41 CFR 102–

34.335) prohibits the use of premium 

grade gasoline in any motor vehicle 

owned or leased by the Government 

unless the motor vehicle specifically 

requires premium grade gasoline. This 

section states that drivers are to use the 

grade (octane rating) of gasoline 

recommended by the motor vehicle 

manufacturer when fueling motor 

vehicles owned or leased by the 

Government. 

As a result of the catastrophic 

destruction caused by Hurricanes 

Katrina and Rita, agencies have reported 

that their vehicles operators are unable 

to purchase lower octane gasoline for 

their vehicles to complete their 

missions. In many areas, agencies have 

only been able to procure premium 

gasoline for use in their motor vehicles. 

The original intent of section 102–

34.335 was to reduce fuel costs and 

eliminate the unnecessary use of 

premium gasoline in vehicles capable of 

being operated on lower grade gasoline. 

A notice announcing this deviation 

was published in the Federal Register 

on September 16, 2005 (70 FR 54747) as 

a result of Hurricane Katrina. This 

notice amends that notice by including 

all agencies whose purchase of gasoline 

for motor vehicles has been impacted by 

both Hurricanes Katrina and Rita. 

B. Procedures 

This deviation is located on the 

Internet at www.gsa.gov/vehiclepolicy 

and clicking on ‘‘Deviation from 41 CFR 

102–34.335’’. 

Dated: September 30, 2005. 

Becky Rhodes, 

Deputy Associate Administrator. 

[FR Doc. 05–20375 Filed 10–11–05; 8:45 am] 

BILLING CODE 6820–14–S 

GENERAL SERVICES 

ADMINISTRATION 

Federal Travel Regulation (FTR) 

Maximum Per Diem Rates for Florida 

and Ohio 

AGENCY: Office of Governmentwide 

Policy, General Services Administration 

(GSA). 

ACTION: Notice of Per Diem Bulletin 06–

2, revised continental United States 

(CONUS) per diem rates. 

SUMMARY: The General Services 

Administration (GSA) is making a 

technical correction to the lodging rates 

of certain locations in the States of 

Florida and Ohio. The per diems 

prescribed in Bulletin 06–2 may be 

found at www.gsa.gov/perdiem. 

DATES: This notice is effective [enter 

date of publication in the Federal 

Register] and applies to travel 

performed on or after October 1, 2005. 

FOR FURTHER INFORMATION CONTACT: For 

clarification of content, contact Lois 

Mandell, Office of Governmentwide 

Policy, Travel Management Policy, at 

(202) 501–2824. Please cite FTR Per 

Diem Bulletin 06–2. 

SUPPLEMENTARY INFORMATION: 

A. Background 

After an analysis of the per diem rates 

established for FY 2006 (see the Federal 

Register notices at 70 FR 52100, 

September 1, 2005), a technical 

correction is being made to the per diem 

rates in the following locations: 

State of Florida 

• Brevard County 

State of Ohio 

• Cuyahoga County 

B. Procedures 

Per diem rates and the FTR Per Diem 

Bulletin are published on the Internet at 

www.gsa.gov/perdiem. A Federal Notice 

is published in the Federal Register on 

a periodic basis. This process ensures 

timely increases or decreases in per 

diem rates established by GSA for 

Federal employees on official travel 

within CONUS. Notices published 

periodically in the Federal Register, 

such as this one, now constitute the 

only notification of revisions in CONUS 

per diem rates to agencies. 

Dated: October 5, 2005. 

Rebecca Rhodes, 

Deputy Associate Administrator. 

[FR Doc. 05–20374 Filed 10–11–05; 8:45 am] 

BILLING CODE 6820–14–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

Statement of Organization, Functions, 

and Delegations of Authority 

Part T (Agency for Toxic Substances 

and Disease Registry) of the Statement 

of Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (50 FR 25129–25130, dated 

June 17, 1985, as amended most 

recently at 69 FR 60629, dated October 

12, 2004) is amended to reflect the 

reorganization of the Agency for Toxic 

Substances and Disease Registry 

(ATSDR). 

Section T–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in its entirety the functional 

statements for the Division of Health 

Studies (TB8), and insert the following: 

Division of Health Studies (TB8). (1) 

Coordinates all activities associated 

with human health studies, surveillance 

activities, and registries; (2) provides 

medical epidemiologic, and 

biostatistical assistance and 

consultation; (3) implements extramural 

research programs that involve human 

health investigations. 

Office of the Director (TB81). (1) 

Plans, directs, coordinates, and manages 

the operations of the Division of Health 

Studies; (2) develops goals and 

objectives and provides leadership, 

policy formulation, and guidance in 

program planning and development; (3) 

facilitates the science, including 

analytic support of the division and 

undertakes special scientific activities; 

(4) coordinates division activities with 

other components of ATSDR and other 

federal agencies. 

Surveillance and Registries Branch 

(TB82). (1) Designs and conducts 

surveillance and registry programs to 

evaluate the adverse health effects on 

persons exposed to hazardous 

substances; (2) conducts health followup activities resulting from surveillance 

and registries; (3) implements 

extramural research programs that 

involve surveillance and registries. 

Health Investigations Branch (TB84). 

(1) Designs and conducts human health, 

including epidemiologic, studies to 

evaluate the association between 

exposure to hazardous substances and 

adverse health effects; (2) provides 

expert medical and environmental 

epidemiologic consultation; (3) 

implements extramural research 

programs that involve human health 

investigations. 

59350 Federal Register / Vol. 70, No. 196 / Wednesday, October 12, 2005 / Notices 

Dated: June 3, 2005. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 05–20369 Filed 10–11–05; 8:45 am] 

BILLING CODE 4160–70–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following Federal 

Committee meeting. 

Name: Advisory Committee on 

Immunization Practices (ACIP). 

Times and Dates: 

8:30 a.m.–5:15 p.m., October 26, 2005. 

8 a.m.–3:30 p.m., October 27, 2005. 

Place: Atlanta Marriott Century Center, 

2000 Century Boulevard, N.E., Atlanta, 

Georgia 30345–3377. 

Status: Open to the public, limited only by 

the space available. 

Purpose: The Committee is charged with 

advising the Director, CDC, on the 

appropriate uses of immunizing agents. In 

addition, under 42 United States Code 1396s, 

the Committee is mandated to establish and 

periodically review and, as appropriate, 

revise the list of vaccines for administration 

to vaccine-eligible children through the 

Vaccines for Children (VFC) program, along 

with schedules regarding the appropriate 

periodicity, dosage, and contraindications 

applicable to the vaccines. 

Matters to Be Discussed: The agenda will 

include discussions on influenza; 

recommendations for use of Hepatitis A 

vaccine among children; VFC vote on 

Hepatitis A; adult Hepatitis B vaccine 

recommendation; varicella zoster immune 

globulin; recommended childhood and 

adolescent immunization schedules; use of 

Tdap vaccine; prevention of rotavirus 

gastroenteritis; Measles, Mumps, Rubella 

Vaccine (MMRV) recommendation; VFC vote 

on MMRV; Human Papailloma Virus vaccine; 

general recommendations on immunization; 

herpes zoster; and Departmental updates. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Demetria Gardner, Epidemiology and 

Surveillance Division, National 

Immunization Program, CDC, 1600 Clifton 

Road, NE., (E–61), Atlanta, Georgia 30333, 

telephone 404/639–8096, fax 404/639–8616. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both the CDC and ATSDR. 

Dated: October 5, 2005. 

Alvin Hall, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 05–20381 Filed 10–11–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2005N–0393] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Investigational 

New Drug Regulations 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension of an existing collection of 

information, and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

requirements under which the clinical 

investigation of the safety and 

effectiveness of unapproved new drugs 

and biological products can be 

conducted. 

DATES: Submit written or electronic 

comments on the collection of 

information by December 12, 2005. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to:http://www.fda.gov/ 

dockets/ecomments. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Karen Nelson, Office of Management 

Programs (HFA–250), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–1482. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Investigational New Drug Regulations—

21 CFR Part 312 (OMB Control Number 

0910–0014)—Extension 

FDA is requesting OMB approval for 

the reporting and recordkeeping 

requirements contained in the FDA 

regulation ‘‘Investigational New Drug 

Application’’ in part 312 (21 CFR part 

312). This regulation implements 

provisions of section 505(i) of the 

Federal Food, Drug, and Cosmetic Act 

(the act) (21 U.S.C. 355(i)) to issue 

regulations under which the clinical 

investigation of the safety and 

effectiveness of unapproved new drugs 

and biological products can be 

conducted. 

FDA is charged with implementing 

statutory requirements that drug 

products marketed in the United States 

be shown to be safe and effective, 

properly manufactured, and properly 

labeled for their intended uses. Section 

505(a) of the act provides that a new 

drug may not be introduced or delivered 

for introduction into interstate 

commerce in the United States unless 

FDA has previously approved a new 

drug application (NDA). FDA approves